Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
March 05 2018 - 7:30AM
At three upcoming investor conferences in March, Conatus
Pharmaceuticals Inc. (NASDAQ:CNAT) President, Chief Executive
Officer and co-founder, Steven J. Mento, Ph.D., and Conatus
Executive Vice President, Chief Operating Officer and Chief
Financial Officer, Keith W. Marshall, Ph.D., M.B.A., will focus on
the company’s expected announcements of clinical trial results.
“We intend to use the upcoming conferences to provide context
for our four planned data readouts, the first being the
announcement of top-line results from our POLT-HCV-SVR trial in the
second quarter,” said Dr. Mento. “This randomized,
placebo-controlled Phase 2b trial is evaluating two years of
treatment with emricasan, our first-in-class pan-caspase inhibitor,
in post-orthotopic liver transplant (POLT) recipients with liver
fibrosis or cirrhosis post-transplant as a result of recurrent
hepatitis C virus (HCV) infection who have successfully achieved a
sustained viral response (SVR) following HCV antiviral
therapy.”
“In collaboration with Novartis, we expect to announce top-line
results from four ongoing Phase 2b clinical trials in 2018 and
2019, including the POLT-HCV-SVR trial, two trials in nonalcoholic
steatohepatitis (NASH) cirrhosis, and one in NASH fibrosis,” said
Dr. Marshall. “We are also advancing with our independent pipeline
expansion activities and expect to provide further updates later
this year. We believe our current financial resources, together
with the anticipated reimbursements for 50% of the costs for the
four ongoing clinical trials, without including any potential
milestone payments under the Novartis collaboration, are sufficient
to maintain operations through top-line results from all four Phase
2b clinical trials by the end of 2019, as well as to fund initial
pipeline expansion activities.”
- At the Roth Capital Partners 30th Annual Conference (March
11-14 in Laguna Niguel, CA), Dr. Mento will participate in two
panel discussions on NASH cirrhosis on Monday, March 12, as part of
the integrated Spring NASH Bash. Dr. Mento and Dr. Marshall will
meet with investment professionals and will provide an overview and
update presentation beginning at 1:30 p.m. ET on Monday, March
12.
- At the H.C. Wainwright 2nd Annual NASH Investor Conference
(March 19 in New York), Dr. Marshall will present a NASH-focused
presentation beginning at 3:40 p.m.
- At the Oppenheimer Healthcare Conference (March 20-21 in New
York), Dr. Mento and Dr. Marshall will meet with investment
professionals and will provide an overview and update presentation
beginning at 10:20 a.m. ET on Wednesday, March 21. An audio webcast
and copy of the Oppenheimer conference presentation will be
available in the Investors section of the company’s website at
www.conatuspharma.com.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease. In
collaboration with Novartis, Conatus is developing its lead
compound, emricasan, for the treatment of patients with chronic
liver disease. Emricasan is a first-in-class, orally active
pan-caspase inhibitor designed to reduce the activity of enzymes
that mediate inflammation and apoptosis. Conatus believes that by
reducing the activity of these enzymes, caspase inhibitors have the
potential to interrupt the progression of a variety of diseases.
For additional information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements, including
statements regarding: the timelines to announce results from
the four ongoing clinical trials; expansion of the company’s
development pipeline; the sufficiency of current financial
resources to maintain operations through 2019, as well as to fund
initial pipeline expansion activities; and caspase inhibitors'
potential to interrupt the progression of a variety of
diseases. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar
expressions. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including those risks
described in the company’s prior press releases and in the periodic
reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in the
company’s forward-looking statements may not be achieved or occur
and actual results could differ materially from those projected in
the forward-looking statements. Except as required by applicable
law, the company does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Jul 2023 to Jul 2024